![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 25, 2021
January 25, 2021
The co-chairs look ahead to the new year, and acknowledge key successes from 2020—despite its many challenges
January 25, 2021
This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
January 25, 2021
This phase II/III study, led by Dr. Shishir Maithel, is assessing the role of neoadjuvant therapy for patients with incidental gallbladder cancer
January 25, 2021
Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
January 25, 2021
This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma
January 25, 2021